- Home
- CALC vs MDCX Comparison
CALC vs MDCX Comparison
Compare CALC & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CALC | MDCX |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.5M | 53.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CALC | MDCX |
|---|---|---|
| Price | $6.04 | $1.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $14.50 | ★ $23.50 |
| AVG Volume (30 Days) | 149.0K | ★ 366.2K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.42 | $1.55 |
| 52 Week High | $6.40 | $8.94 |
Technical Indicators
Market Signals| Indicator | CALC | MDCX |
|---|---|---|
| Relative Strength Index (RSI) | 73.00 | 32.88 |
| Support Level | $4.64 | $1.68 |
| Resistance Level | $6.40 | $2.03 |
| Average True Range (ATR) | 0.50 | 0.19 |
| MACD | 0.14 | -0.03 |
| Stochastic Oscillator | 84.85 | 5.19 |
Price Performance
Historical ComparisonAbout CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
About MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.